Clinical trials continue to be a cornerstone to the effort to advance care and improve outcomes for cancer patients. ECOG and ACRIN collectively have over 65 years of experience conducting high impact clinical trials that have helped shaped clinical practice. In response to the National Clinical Trials Network (NCTN) initiative, ECOG and ACRIN have merged their complementary scientific programs to form the ECOG-ACRIN Cancer Research Group (E-A). We propose a program focused on the efficient development and implementation of practice-changing science along the cancer care continuum from early detection through treatment of advanced disease. We take advantage of combined expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management center at the Dana Farber Cancer Institute and Brown University, to propose a portfolio of treatment and advance imaging trials that recognize the importance of biomarkers to identify appropriate patient subgroups for precisely targeted intervention. The E-A biorepositories, image database and associated translational science centers will leverage the data collected in the context of trials to perform correlative science studies that advance our understanding of cancer biology and treatment effect. We continue to seamlessly integrate with Cancer Center and SPORE research programs to create an interface for translating NCI-supported science into clinical trials and to attract junior investigators intothe NCTN. We propose to continue collaborating across the NCTN, contributing high quality trials, leadership in advance imaging, joint trial development and important NCTN operational infrastructure. E-A will leverage unique clinical informatics expertise to contribute a data warehouse of annotated images and specimens, laboratory analytics and clinical data to foster scientific discovery. E-A will contribute an accrual network of 37 main member institutions, 200 affiliates, 36 CCOPs and minority-based CCOPs that have accrued 33750 patients to clinical trials over the last 6 years. E-A is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients.

Public Health Relevance

The primary goal of ECOG-ACRIN is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180820-01
Application #
8605648
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-29
Project End
2019-02-28
Budget Start
2014-04-29
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$12,470,376
Indirect Cost
$745,344
Name
Ecog-Acrin Medical Research Foundation
Department
Type
DUNS #
078579855
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2017) Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02. Neuro Oncol :
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Bernard, Brandon; Muralidhar, Vinayak; Chen, Yu-Hui et al. (2017) Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123:1536-1544
Zhao, Fengmin; Cella, David; Manola, Judith et al. (2017) Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer :

Showing the most recent 10 out of 199 publications